Advances in glioblastoma therapy: an update on current approaches

RS Angom, NMR Nakka, S Bhattacharya - Brain sciences, 2023 - mdpi.com
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …

Glioblastoma therapy: past, present and future

E Obrador, P Moreno-Murciano… - International journal of …, 2024 - mdpi.com
Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

γδ T cells as a potential therapeutic agent for glioblastoma

I Kang, Y Kim, HK Lee - Frontiers in Immunology, 2023 - frontiersin.org
Although γδ T cells comprise a small population of T cells, they perform important roles in
protecting against infection and suppressing tumors. With their distinct tissue-localizing …

Azithromycin inhibits glioblastoma angiogenesis in mice via inducing mitochondrial dysfunction and oxidative stress

X Zhang, H Xu - Cancer Chemotherapy and Pharmacology, 2023 - Springer
The poor outcomes in glioblastoma (GBM) necessitate new treatments. As GBM is highly
vascularized and its growth is largely dependent on angiogenesis, angiogenesis inhibitors …

Emerging Therapies for Glioblastoma

SA Rios, S Oyervides, D Uribe, AM Reyes, V Fanniel… - Cancers, 2024 - mdpi.com
Simple Summary Glioblastoma is the most common malignant brain cancer and is
associated with poor prognosis, with an average survival after diagnosis of less than 18 …

ROS regulation in gliomas: implications for treatment strategies

YC Yang, Y Zhu, SJ Sun, CJ Zhao, Y Bai… - Frontiers in …, 2023 - frontiersin.org
Gliomas are one of the most common primary malignant tumours of the central nervous
system (CNS), of which glioblastomas (GBMs) are the most common and destructive type …

Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock

N Nelson, A Relógio - NPJ Precision Oncology, 2024 - nature.com
Glioblastoma is one of the most lethal cancers with current therapeutic options lacking major
successes. This underlines the necessity to understand glioblastoma biology on other levels …

[HTML][HTML] Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study

Y Liao, X Bai, Y Cao, M Zhang - Journal of Clinical Neuroscience, 2024 - Elsevier
Background We retrospectively analyzed the effects of low-dose bevacizumab (BEV)
combined with temozolomide (TMZ) on health-related quality of life (HRQL) in patients with …

[HTML][HTML] Reprogramming of astrocytes and glioma cells into neurons for central nervous system repair and glioblastoma therapy

J Wei, M Wang, S Li, R Han, W Xu, A Zhao, Q Yu… - Biomedicine & …, 2024 - Elsevier
Central nervous system (CNS) damage is usually irreversible owing to the limited
regenerative capability of neurons. Following CNS injury, astrocytes are reactively activated …

Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment

A Berro, A Assi, M Farhat, L Hatoum, JP Saad… - Critical Reviews in …, 2024 - Elsevier
Purpose This systematic review summarizes evidence of VEGFR gene mutations and
VEGF/VEGFR protein expression in glioblastoma multiforme (GBM) patients, alongside the …